Tonix Pharmaceuticals heads into its May 7 earnings print with an unusual configuration: options traders are leaning bullish, short sellers are piling in — and a fresh Wall Street initiation has landed right in the middle.
Short positioning has jumped sharply ahead of the report. SI % of FF climbed from roughly 13.5% in late April to 17.6% now — a 30% week-on-week surge in shares short. Days to cover stands at 8.8, the highest it has been in months. Yet the borrow market hasn't tightened to match. The cost to borrow has actually eased over the past month, now at 3.7% versus above 5% in March, and the 52-week availability peak of 100% suggests lending supply has been more than adequate for bears adding exposure. The short score reads 76.5 out of 100, near the top of its recent range — short-side pressure is real, but this is not a squeeze-ready setup.
Options positioning tells a different story. The put/call ratio has dropped to 0.30, well below its 20-day average of 0.46, pointing to call-dominated activity into the print. That is close to the lowest reading of the past year. The divergence is striking: short sellers are adding aggressively while options flow tilts toward upside speculation. One catalyst sharpening the bull case arrived on Monday when TD Cowen initiated coverage with a Buy rating and a $22 price target — meaningful upside against the current price of $13.03. The company's EPS surprise rank is in the 81st percentile, meaning it has a strong track record of beating estimates.
Fundamental context frames the debate plainly. Tonix carries a pre-revenue biotech profile, with estimated net losses approaching $150 million against projected revenue of $31.5 million. The pipeline catalysts are the story. Ahead of the print, Tonix presented Phase 1 data for TNX-4800, its anti-Borrelia antibody targeting Lyme disease prevention, and announced plans for an adaptive Phase 2 field study — a development that likely underpins the fresh analyst coverage. CEO Seth Lederman has been consistent in his own buying, adding 20,000 shares over the past 90 days at prices around $13–15, a pattern worth noting even if the dollar amounts are modest.
Past earnings prints have been volatile but not uniformly bearish. The prior two events produced 5-day moves of roughly +13% on each occasion, even when the 1-day reaction was muted or slightly negative. The print on May 7 tests whether the TD Cowen thesis and the pipeline readouts can hold up against a short base that has just grown by nearly a third in a single week.
See the live data behind this article on ORTEX.
Open TNXP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
